Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)

Completed

Conditions studied: Multiple Myeloma (MM)

In brief

Multiple myeloma (MM) is a rare cancer caused by abnormal survival of plasma cells (blood cells). Most trial participants with MM relapse (cancer has come back) or become non- responsive to treatment and remission gets shorter after each line of treatment. This is a study to assess t(11;14) and BCL2 expression in adult participants with newly diagnosed and relapsed/refractory (R/R) MM. Approximately 500 adult participants with newly confirmed or relapsed/refractory (R/R) multiple myeloma (MM) will be enrolled in around 15-20 countries. Participants will receive standard of care while participating in this study. No drug will be administered as a part of this study. Participants will attend regular visits during the course of the study at a hospital or clinic and will be asked to provide bone marrow and blood samples.

Key facts

Study ID

NCT04721002

Run by

AbbVie

People needed

514

Starts

2021-07-07

Expected to finish

2023-09-30

Last updated by the study team

2023-10-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed newly diagnosed or relapsed/refractory (R/R) Multiple myeloma (MM) who have signed informed consent for the use of their biological material for research purposes.

You may not qualify if…

• Participants who do not have Bone Marrow (BM) and blood sample at time of diagnosis or at confirmation of relapse.

Where it is running

• Tulane School of Medicine /ID# 223864 — New Orleans, Louisiana, United States
• University of Texas Southwestern Medical Center /ID# 223865 — Dallas, Texas, United States
• Hospital Italiano de Buenos Aires /ID# 224153 — Ciudad Autonoma Buenos Aires, Buenos Aires F.D., Argentina
• Alfred Health /ID# 224386 — Melbourne, Victoria, Australia
• Hospital São Rafael /ID# 224307 — Salvador, Estado de Bahia, Brazil
• Hospital de Clinicas de Porto Alegre /ID# 224274 — Porto Alegre, Rio Grande do Sul, Brazil
• Clinica Sao Germano /ID# 224239 — São Paulo, São Paulo, Brazil
• Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein /ID# 224303 — São Paulo, São Paulo, Brazil
• Instituto COI de Educacao e Pesquisa /ID# 224245 — Rio de Janeiro, Brazil
• Real e Benemérita Associação Portuguesa de Beneficência /ID# 224305 — São Paulo, Brazil
• Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo /ID# 225749 — São Paulo, Brazil
• Cross Cancer Institute /ID# 224172 — Edmonton, Alberta, Canada
• Klinicki bolnicki centar Zagreb /ID# 226969 — Zagreb, City of Zagreb, Croatia
• Fakultni nemocnice Hradec Kralove /ID# 224089 — Hradec Králové, Czechia
• Fakultni nemocnice Ostrava /ID# 224090 — Ostrava, Czechia
• CHRU Lille - Hopital Claude Huriez /ID# 228919 — Lille, Hauts-de-France, France
• CHU de Nantes, Hotel Dieu -HME /ID# 223702 — Nantes, Pays de la Loire Region, France
• AP-HP - Hopital Necker /ID# 228062 — Paris, France
• Praxis am Volkspark /ID# 224763 — Berlin, Germany
• Asklepios Klinik Altona /ID# 224761 — Hamburg, Germany
• Alexandra General Hospital /ID# 224828 — Athens, Attica, Greece
• Beaumont Hospital /ID# 225514 — Beaumont, Dublin, Ireland
• Hadassah Medical Center-Hebrew University /ID# 224884 — Jerusalem, Jerusalem, Israel
• Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona /ID# 224690 — Ancona, Italy
• ASST Grande Ospedale Metropolitano Niguarda /ID# 224608 — Milan, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.